Remark Holdings, Inc. (NASDAQ:MARK)

Remark Holdings, Inc. (NASDAQ:MARK) AI Key To Future Growth

Remark Holdings, Inc. (NASDAQ:MARK)

Shares of Remark Holdings, Inc. (NASDAQ:MARK) gained 5.98% as investors reacted to the company’s 3D augmented reality product being selected as the core technology behind Sina Weibo new mobile application. Developed by the company’s wholly-owned subsidiary, KanKan, the 3D facial tracking technology can track and recognize movements of various facial features.

Remark Holdings, Inc. (NASDAQ:MARK)

Sina Weibo Collaboration

According to the company’s Chief Executive Officer, Kai-Shing Tao, integration of the technology in Sina Weibo app, SuishouPai app, demonstrates the company’s ability to monetize its technologies. The use of the facial recognition technology should also help Remark Holdings better understand various facial expression which could lead to further improvements in the AI technology.

“We not only created a facial tracking system that we believe is far superior to existing technologies, but we also created 3D filters that can be used socially among friends or used to identify business opportunities in various industries, such as in the cosmetics field,” Tao in a statement.

Some observers believe that the value of the Sina Weibo deal has yet to be fully factored into the stock price of Remark Holdings, Inc. (NASDAQ:MARK). The share price has struggled to break through the $3 -$4.50 trading range despite the value of the assets that the company owns.

The stock is currently rated as a ‘strong buy’ by one analyst firm according to data compiled by Zacks Investment Research.

KanKan AI Prospects

KanKan has inked lucrative deals with tech giants Alibaba Group Holding Ltd (NYSE:BABA), Tencent Holdings Ltd (OTCMKTS:TCEHY) and Sina Weibo, something that could have catapulted the stock up the charts. However, that has not been the case. The management has already indicated that the recently announced deals have the potential to take the company’s artificial revenue from zero as of the start of the year, to $20 million as of next year.

The expected revenue could be much higher as tech giants continue to come up with unique ways of integrating artificial intelligence into their operations and products. The Remark Holdings subsidiary could continue to elicit interest given the investment it has made on the emerging technological spectacle.

“Artificial intelligence is the most exciting and disruptive force in technology today. It has the power to rapidly change business fundamentals. Remark’s AI technology platforms are on the forefront,” said Tao.

A further testament to Remark Holdings, Inc. (NASDAQ:MARK) credibility on AI is the naming of KanKan latest product, Heterogeneous Multi-Intelligence System, among the top three in Alibaba’s ‘Best AI Products’.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MARK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) Drops

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) felt the wrath of Wall Street after announcing the pricing of a $5.1 million public offering of common stock. Shares of the clinical stage pharmaceutical company fell 46.9%, to end Thursday’s trading session at $0.45 a share.

Atossa Genetics Inc. (NASDAQ:ATOS)

Public Offering Reaction

The company has priced 11.5 million shares of common stock at a public offering price of $0.44 a share. Atossa Genetics Inc. (NASDAQ:ATOS) has also granted underwriters an overallotment option for the purchase of 1 million additional shares of common stock. Gross proceeds before deduction of underwriting discounts, commissions, and other estimated offering costs should be about $5.1 million.

Atossa Genetics Inc. (NASDAQ:ATOS) plans to use net proceeds from the offering for general corporate purposes. The offering should close on or about October 30, 2017.

The $5.1 million public offering appears to have spooked investors as the stock dropped from $1.50 a share to $0.45. Following the slump, the stock is now down by more than 40% for the year.

Oral Endoxifen Trials

The pricing of the public offering comes just days after the clinical stage pharmaceutical company announced preliminary results from its Phase 1 study of Oral Endoxifen. The company is investigating the drug for the treatment of recurrent breast cancer.

Trial results indicate that Endoxifen met all its objectives with no clinically significant safety signals or adverse events reported. Oral Endoxifen was also well tolerated at each dose levels. According to Atossa Genetics Inc. (NASDAQ:ATOS), the study results demonstrate the sustainability of oral Endoxifen for further clinical development.

“Based on these positive preliminary results, we are advancing our oral Endoxifen into Phase 2 studies,” commented Dr. Steven C. Quay, CEO, and President. “We expect our initial Phase 2 study will be in women who are refractory to Tamoxifen and we expect to begin that study in the first quarter of 2018,” continued Dr. Quay.

Estimates indicate that about 250,000 women will be diagnosed with breast cancer in the U.S this year with 40,000 expected to die. Breast cancer is the second leading cause of cancer death in the US. Atossa Genetics Inc. (NASDAQ:ATOS) estimates the potential market for its oral and tropical formulation of Endoxifen if approved at over $1 billion.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Quotient Ltd (NASDAQ:QTNT) Reports 99.8% Blood Grouping Concordance

Quotient Ltd (NASDAQ:QTNT)

Quotient Ltd (NASDAQ:QTNT) shares gained 11.9% after the diagnostics company reported positive concordance data from MosaiQ Verification and validation studies in blood grouping. According to the Chief Executive Officer, Paul Cowan, 99.8% blood grouping concordance demonstrates the robustness of MosaiQ as a diagnostics platform.

Quotient Ltd (NASDAQ:QTNT)

MosaiQ Platform Development

The positive study results mark an important milestone in the development of the highly informative and disruptive testing platform for transfusion diagnostics. Quotient Limited has also demonstrated feasibility of the platform with respect to detection of nucleic acids.

Over the next 12 months, Quotient Ltd (NASDAQ:QTNT) plans to carry out European field trials and then file for European regulatory approval. MosaiQ European commercialization has already began with the company expecting tender offers in FY2018.

Quotient Ltd (NASDAQ:QTNT) stock gapped higher on the news – touching highs of $5.52 a share before it dropped to end Wednesday’s trading session at $5.19.

Private Placement

In addition, Quotient Ltd (NASDAQ:QTNT) has entered into agreements with certain shareholders for the issuance of 7.9 million shares priced at $4.64 a share. The company has also issued 550,000 pre-funded warrants at $4.75 and exercisable for up to 550,000 ordinary shares, priced at $0.01 per ordinary share.

Quotient Ltd (NASDAQ:QTNT) expects aggregate proceeds of $40 million from the private placement. The company expects an additional $49 million on the exercise of 8.4 million warrants priced at $0.125 a warrant. Net proceeds from the offering are to be used to fund the ongoing development and commercial scale-up of MosaiQ and for working capital among other general corporate purposes. The offering should close on or about October 26, 2017.

“I am also pleased that we have strengthened our balance sheet through our recently announced private placement, which was led by a small group of existing shareholders, with participation by directors and management. This financing is an added vote of confidence for what we have achieved to date and what we have the potential to achieve in the future,” said Mr. Cowan.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $QTNT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pulmatrix Inc. (NASDAQ:PULM)

Pulmatrix Inc. (NASDAQ:PULM)’s PUR1900 Awarded Designation

Pulmatrix Inc. (NASDAQ:PULM)

Shares of Pulmatrix Inc. (NASDAQ:PULM) fell 4.86% in Tuesday’s trading session to end the day at $1.76 a share. The sell-off comes just days after the U.S. Food and Drug Administration (FDA) designated the clinical stage biopharmaceutical company’s candidate drug, Pulmazole (PUR1900), as a Qualified Infectious Disease Product (QIDP).

Pulmatrix Inc. (NASDAQ:PULM)

FDA Designation

The designation is designed to speed up the development of novel drugs that have the potential to address important pathogens. Pulmatrix stands to enjoy up to 5 years of market exclusivity should the drug succeed in clinical trials and gain regulatory approval.

The candidate drug has already achieved orphan drug designation for the treatment of fungal infections in the airways of patients with cystic fibrosis. The QIDP designation further expands PUR 1900 status to include Asthma patients

“This second QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to severe asthma patients suffering from fungal lung infections,” said Pulmatrix CEO Robert Clarke, PhD. “It will give us the benefit of an expedited regulatory review and significantly expands the potential population we can treat with our Pulmazole product.

Patent Protection Milestone

In addition to FDA designation milestones, Pulmatrix Inc. (NASDAQ:PULM) has received two important patents from the United States Patent and Trademark Office (USPTO). One of the patents expands the potential of the company’s technology for delivering drugs directly to the lungs.

The company has developed a dry powder that it claims can fly easily through the airways and deliver a wide range of types of drugs. The technology is designed to increase the efficiency of drug delivery while also reducing the side effects associated with existing approaches.

The second patent expands the patent protection of Pulmatrix Inc. (NASDAQ:PULM) candidate drug PURO200 for the treatment of chronic obstructive pulmonary disease. The new patent broadens the intellectual property protection so that it is no longer limited to specific characteristics and performance criteria.

“The new PUR0200 patent will make it more difficult for potential competitors to develop similar products or to work around our product candidate,” explained Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. “The new claims also will make it possible for us to add in a second therapeutic to create a combination product.”

Pulmatrix Inc. (NASDAQ:PULM) is currently developing PUR0200 in Europe and the United States, following regulatory pathways that offer quickest approvals.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PULM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OpGen Inc. (NASDAQ:OPGN)

OpGen Inc. (NASDAQ:OPGN) Awarded $860,000 CDC Contract

OpGen Inc. (NASDAQ:OPGN)

Shares of OpGen Inc.(NASDAQ:OPGN) fell 1.4% after the Center for Disease Control and Prevention awarded the company a contract for the development of clinical support tools for antimicrobial stewardship and infection control. The agency has since granted the company $860,000 for the development of a cloud-based mobile software which is to be used in low and middle-income countries.

OpGen Inc. (NASDAQ:OPGN)

CDC Contract Award

OpGen Inc. (NASDAQ:OPGN) is to work with Teqqa, LLC and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc. to bring the solution to fruition. Teqqa is to provide a cloud and mobile based software platform to support antimicrobial stewardship.

The platform is to be used to identify patients that require infection control precautions and assist in the implementations of the necessary precautions. The software will be translated into Spanish to support WHONET data integration.

“OpGen looks forward to working with the CDC to help address this urgent global need,” stated Evan Jones, CEO of OpGen. “Improving antimicrobial stewardship worldwide has been identified by the CDC, the World Health Organization (WHO) and governments worldwide as a core activity in the fight to contain and manage infections from multidrug-resistant pathogens.”

OpGen Inc. (NASDAQ:OPGN) is also developing the Acuitas AMR Gene Panel u5.47, a PCR test designed to detect antibiotic resistance genes. The test can detect up to five bacterial pathogens in clinical isolate and urine specimens. It can also be used to detect up to 47 antimicrobial resistance genes.

According to OpGen’s senior vice president of research and development, Dr. Terry Walker, antimicrobial drug resistance is an urgent global health concern.

“Our data show that the Acuitas AMR Gene Panel accurately detects and quantitates key complicated urinary tract infection pathogens. We are encouraged by the development data for Acuitas Lighthouse Knowledgebase prediction algorithms currently in development,” said Dr. Walker.

OPGN Stock Performance

The CDC award did little to strengthen investor confidence in the precision medicine company. The stock has underperformed the overall industry, having shed more than 70% in market value since the start of the year.

OpGen Inc. (NASDAQ:OPGN) is currently trading in a downtrend as investors sentiments on the street continue to drop. However, the stock is currently rated as a ‘strong buy’ by two analyst firms according to data compiled by Zacks Investment Research.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) Trades Higher

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC)

BITCOIN SERVICES I COM USD0.001(OTCMKTS:BTSC) shares received a boost after bitcoin gained more than 5% in Friday’s trading session to close in on a new record high of $6000. The stock gained 8.25% to end the week at $0.0667.

Bitcoin’s impressive run has seen its market grow to about $100 billion. Initial Coin Offerings have achieved an average return of 790% over the past six months.

BITCOIN SERVICES I COM USD0.001(OTCMKTS:BTSC)

BTSC Stock Performance

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) is currently trading near a key support level at $0.06, below which the stock faces the risk of erasing a good chunk of gains accrued since the start of the year. The stock is up by more than 400% for the year after benefiting from the growing popularity of digital currencies.

However, the stock is currently trading in a range after dropping from $0.21 to current trading levels. Failure of Bitcoin Services to issue updates about its operations and prospects in the bitcoin mining business has been the biggest undoing in fueling investor concerns.

Business Update

Investor’s confidence has taken a hit as most of them switch their attention to other stocks that provide detailed information about their operations. The last update came in August when the company unveiled a new corporate website and announced the launch of its digital cash Dash that can be used to make instant private payments online or in-store using secure and open source platform.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) also announced the creation of a new subsidiary dubbed Crypto Capital Corp that was to develop a Crypto-currency wallet. The big plan was to provide a way for people to safely store multiple digital currencies in one location.

In May, the bitcoin manufacturing company announced it had begun mining Monero, one of the top digital currencies with a market cap of over $300 million. Early this year Bitcoin Services purchased four Antminer S9 bitcoin miners as it sought to support its growth prospects.

BITCOIN SERVICES I COM USD0.001 (OTCMKTS:BTSC) operates three core business – bitcoin escrow services, bitcoin mining, and blockchain software development. Its principal products and services are the mining of bitcoin as well as providing escrow services for buyers and sellers and bitcoin.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BTSC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Rennova Health Inc. (NASDAQ:RNVA) Revenue Stream Strengthened

Rennova Health Inc. (NASDAQ:RNVA)

Rennova Health Inc. (NASDAQ:RNVA) shares fell 20.2% after the company announced its Big South Medical Center had been granted a three-year certificate of accreditation by the Center for Medicare and Medicaid Services. According to the Chief Executive officer, Seamus Lagan, the certification paves way for the company to start receiving payments for services rendered.

Rennova Health Inc. (NASDAQ:RNVA)

CMS Accreditation

The certification and opening of the Big South Medical Center signify a new direction to Rennova Health Inc. (NASDAQ:RNVA) and is expected to lead to a reliable revenue stream. The hospital had unaudited annual revenues of $12 million and EBITDA OF $1.3 million in 2015.

Rennova has been a shadow of itself in the stock market. The stock is down by more than 90% for the year after dropping from $44 a share to current $0.98 trading level.

Rennova Health Inc. (NASDAQ:RNVA) is an integrated provider of diagnostic and supportive software solutions through its medical centers. Approximately 60% of the services that the company provides are payable through federal payers.

Some of the services offered by Big South Fork Medical Center include 24/7 emergency services as well as radiology services and X-ray CT scan and ultrasound. Rennova remains optimistic of being able to rebuild Big South Medical Center revenues to levels achieved in 2015, based on the hospital first month of operations.

“Receiving our Medicare number is the final hurdle that will enable us to collect payment for services provided. We look forward to the continued success and growth of this hospital and remain confident that this is an excellent business model to create value for our shareholders,” said CEO Seamus Lagan.

Cigna Suit Win

Separately, Rennova Health Inc. (NASDAQ:RNVA) has won an appeal in an Eleventh Circuit Court of Appeals in a long-running CIGNA Lawsuit. The company’s subsidiaries Bio health Medical Laboratory and PB Laboratories had filed a lawsuit against CIGNA in 2015 accusing the company of failing to pay for laboratories services offered.

A U.S District Court dismissed the laboratory’s claims for lack of standing. The subsidiaries appealed the ruling to the Eleventh Circuit Court of Appeals which on its part found the companies have the standing to raise claims.

“This is an exciting development for us and allows us to push forward in our pursuit of the total amount of our original claims,” said Mr. Lagan.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RNVA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) Slumps 29%

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

Shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) fell 29.7% after the biopharmaceutical company announced the pricing of an underwritten public offering of 3.5 million American Depository Shares at $5 per ADS. The company has also granted underwriters a 30-day option for the purchase of additional 522,000 ADS shares.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)

The company expects gross proceeds of $17.4 million from the offering – assuming underwriters don’t exercise the option to purchase additional shares. Net proceeds from the offering are to be used to fund ongoing clinical development efforts as well as for working capital and other general corporate purposes. The offering should close on or about October 20, 2017, subject to satisfaction of customary closing conditions.

Akari Investors’ Reaction

News of the public offering has not gone well with investors given that, in addition to plunging the company into more debt, the offering will lead to further dilution of the stock. Wednesday’s sell-off accompanied a downtrend that has gripped the stock in recent weeks.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) has shed more than 40% in market value over the past month as sellers continue to push the stock lower. The stock is down by more than 30% for the year and on the brink of dropping to multi-year lows.

Amidst the recent sell-off, William Blair upgraded shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) from ‘Market Perform’ to ‘Outperform’ in a research note to investors. The upgrade came at a time when the stock was trading at the $8.80 per share. The firm, at the time, said the shares of the biopharmaceutical Company were undervalued given the value proposition on the development of candidate drug Coversin.

Coversin Development

Separately, the developer of inhibitors for acute and chronic inflammation has enrolled three additional patients in the ongoing Phase II COBALT clinical trial of Coversin, in patients with paroxysmal nocturnal Hemoglobinuria (PNH). The addition brings to eight the total number of patients under trial. Four of the patients have already moved to the long-term safety study, Converse.

Akari Therapeutics is to issue an update on al PNH patients at the American Society of Hematology Annual Meeting to be held next month. The company has also announced plans to advance Coversin towards Phase III trials in naïve PNH patients. William Blair puts the success probability of the PNH program at 55% with an estimated peak U.S. sales target of $500 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

My Size Inc. (NASDAQ:MYSZ)

My Size Inc. (NASDAQ:MYSZ) Signs ‘Emme’ And Susan Moses

My Size Inc. (NASDAQ:MYSZ)

My Size Inc. (NASDAQ:MYSZ)

Shares of My Size Inc. (NASDAQ:MYSZ) gained 6.22% after the developer of proprietary measurement technologies confirmed the signing of Supermodel Emme and celebrity stylist Susan Moses as brand ambassadors. The two will represent the company as it moves to pursue growth opportunities in the multi-billion, plus-size apparel market.

My Size has set it eyes on the plus-sized women market given that apparel sales in the segment rose 6% last year to highs of $21.4 billion. Emme should help strengthen the company’s prospects in the sector given that in addition to being a TV personality, she is the world’s first curvy supermodel.

Susan Moses, on the other hand, is a renowned retail ambassador and blogger whose signature look has been showcased in multiple red carpets

“We are thrilled to welcome Emme and Susan to the My Size family. We believe that the vast experience, high acclaimed expertise, respected industry insight and overall impeccable sense of style of both ladies is going to lead to amazing opportunities for My Size in the plus size market,” said Ronen Luzon, CEO of My Size, and Inc.

My Size Inc. Patent Award

Separately, My Size Inc. (NASDAQ:MYSZ) has been awarded its first patent, dubbed Measurement of a Body Part smartphone application. Designed for the online apparel market, the application will enable shoppers to choose the correct size garment on a retailer’s website, using measurements taken by their smartphones.

The issuance of the patent should strengthen My Size Inc. (NASDAQ:MYSZ) position as a measurement technology leader. It should also bolster the company’s position in the growing e-commerce apparel market.

“We have many other patents pending worldwide for our Measurement of a Body Part smartphone application as well as other measurement applications in our long pipeline of products which we have developed for the e-commerce and m-commerce apparel,” said Chief Product Officer, Billy Pardo.

My Size Inc. (NASDAQ:MYSZ) proprietary Size IT smart measuring tape is currently available and provides accurate measurement capabilities on any iOS mobile application. The company is also working to make the application available on Android devices.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MYSZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) Struggles To Close Above $6

Celsion Corporation (NASDAQ:CLSN)

Celsion Corporation (NASDAQ:CLSN) shares fell 1.69% after initially rising by 8% in pre-market trading, after the company announced the publication of a manuscript for its Phase III HEAT study, assessing ThermoDox in hepatocellular carcinoma (HCC). The article details findings from a study of 701 patients as well as results from computer simulation studies.

ThermoDox Development

ThermoDox is Celsion’s most advanced tumor-targeting drug delivery technology and employs a novel heat-sensitive liposome to address difficult-to-treat cancers. The program is currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.

“We believe strongly that ThermoDox® may be an important new approach for the treatment of HCC. We are now fully committed to the OPTIMA Study and to learning more about how this combination therapy of standardized RFA plus ThermoDox® may significantly prolong the survival of, if not cure, patients,” said CEO Michael H. Trading.

Celsion Corporation (NASDAQ:CLSN)’s upside run, that began early in the month, is losing its momentum. The stock has struggled to close above the $6 a share on two attempts. Selling pressure appears to be slowly building. The stock has underperformed the industry for the better part of the year and the stock continues to trade at levels last seen in January.

The stock is currently rated as a ‘strong buy’ by two firms and as a ‘hold’ by one firm according to data compiled by Zack Investment Research.

Celsion’s New Financing

Celsion Corporation (NASDAQ:CLSN)

Separately, Celsion Corporation (NASDAQ:CLSN) has entered into Exercise agreements with holders of existing warrants issued in July. Pursuant to the agreement, the company has agreed to issue 2.4 million Series AAA Warrants at an exercise price of $2.07 a share and series BBB Warrants are an exercise price of $4.75 a share.

Celsion Corporation (NASDAQ:CLSN) expects gross proceeds of $15.6 million from the exercise of the Series AAA and Series BBB Warrants. Net proceeds are to be used for general corporate purposes. According to CEO, Michael Trading, the exercise agreements eliminate financial challenges that the company has faced in recent years. The executive also expects the new financing to help accelerate the development of drug candidates in the company’s pipeline.

“This significant capital infusion from the exercise of existing outstanding warrants at their original exercise prices is an example of our strategic approach to financing and is expected to extend the Company’s operating horizon through full patient enrollment of our Phase III OPTIMA Study,” said Mr.  Tardugno.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.